The current debate surrounding access to GLP-1 receptor agonists – drugs like Wegovy and Ozempic – isn’t simply about weight loss or diabetes management; it’s a revealing case study in the evolving relationship between pharmaceutical innovation, regulatory oversight, and market forces. While headlines proclaim an FDA crackdown on “illegal” compounding, the situation is far more nuanced. The agency, under Dr. Marty Makary, is attempting to reassert control over a rapidly shifting landscape where established pathways for drug approval are being challenged by demand and entrepreneurial responses. The core question isn’t whether compounded GLP-1s are inherently dangerous, but whether the current regulatory framework can adequately address the risks associated with a market driven by both legitimate need and profit.
This week, I spoke with Dr. Makary in Washington D.C., amidst a period of significant internal change for the FDA – navigating leadership transitions, budget cuts, and revised policies on vaccines and drug approvals. The agency’s recent reversal regarding Moderna’s mRNA flu shot application, just days before our conversation, further underscores the tensions at play. The FDA initially refused to accept Moderna’s application, then reversed course to review it with a decision slated for August 5th, highlighting a perceived inconsistency that has raised concerns within the industry. Dr. Makary maintained that the FDA’s initial guidance to Moderna was “pretty clear,” emphasizing the need for robust trial design and appropriate comparator products. However, Moderna disputes this characterization, pointing to existing FDA rules and prior communication that suggested their initial trial design was acceptable. This disagreement isn’t merely procedural; it speaks to a broader debate about the flexibility and predictability of the FDA’s regulatory process.
Based on the original CNBC report.
The immediate focus of the FDA’s attention, however, remains the proliferation of mass-compounded GLP-1s. These are versions of drugs like Wegovy created by compounding pharmacies, often marketed through telehealth companies like Hims & Hers. Dr. Makary emphasized the FDA is “serious” about addressing what it views as unlawful activity, citing concerns about quality control, patient safety, and violations of federal law. The agency intends to restrict access to the active pharmaceutical ingredients (APIs) needed for these compounded drugs. The distinction Dr. Makary repeatedly drew was between branded manufacturers, who undergo rigorous clinical trials to demonstrate efficacy and safety, and companies circumventing this process. He stated the FDA is “directly talking to these companies and saying, you have to play by the rules.” While the hope is that 2026 will see an end to illegal mass compounding, the FDA is already observing a shift, with more companies sourcing APIs directly from Novo Nordisk and Eli Lilly – a system Dr. Makary believes “has a path of working,” potentially fostering competition while maintaining a degree of quality control.
However, the narrative of “illegal” compounding is complicated by the immense demand for these drugs and the limited supply from authorized manufacturers. The FDA’s actions, while intended to protect public health, risk exacerbating existing access issues. The agency’s concern centers on the potential for substandard ingredients or incorrect dosages in compounded versions, but the reality is that many patients are turning to these alternatives precisely because they cannot obtain the branded drugs through traditional channels. This creates a situation where the perceived risk of a compounded drug is weighed against the certainty of being unable to access any treatment at all. The FDA’s approach, therefore, must consider not only safety but also the broader implications for patient access and equity.
Beyond GLP-1s, Dr. Makary also raised a critical point about the U.S.’s competitive position in early-stage drug development, warning that the country is falling behind China. He identified bottlenecks in hospital contracting, ethics reviews, and the Investigational New Drug (IND) application process as key impediments to innovation. The FDA, he acknowledged, has added layers of questioning to the IND application over time without removing outdated or redundant inquiries. This bureaucratic burden, he argues, is slowing down the pace of research and hindering the U.S.’s ability to compete with China’s rapidly expanding biotech sector, fueled by significant state investment and streamlined regulatory timelines. Dr. Makary indicated the FDA is exploring potential partnerships with health systems and academic medical centers to accelerate the pre-IND process, signaling a willingness to address these systemic challenges.
Looking ahead, the crucial question isn’t simply whether the FDA will succeed in curbing mass compounding or streamlining the IND process. It’s whether the agency can adapt its regulatory framework to accommodate the accelerating pace of pharmaceutical innovation while upholding its core mission of protecting public health. The ongoing debate over Moderna’s flu shot, the challenges surrounding GLP-1 access, and the growing competition from China all point to a need for a more flexible, transparent, and proactive regulatory approach. Specifically, we should watch for whether the FDA begins to prioritize “real-world evidence” alongside traditional clinical trial data when evaluating new drugs and therapies – a shift that could potentially accelerate access to innovative treatments while still ensuring patient safety.
